Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2021

Is levetiracetam more effective than phenytoin in seizure
cessation in children with convulsive status epilepticus that don’t
respond to first-line treatment?
Sydney A. Santiago
Philadelphia College of Osteopathic Medicine

Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Medicine and Health Sciences Commons

Recommended Citation
Santiago, Sydney A., "Is levetiracetam more effective than phenytoin in seizure cessation in children with
convulsive status epilepticus that don’t respond to first-line treatment?" (2021). PCOM Physician
Assistant Studies Student Scholarship. 587.
https://digitalcommons.pcom.edu/pa_systematic_reviews/587

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student
Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM
Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For
more information, please contact library@pcom.edu.

Is levetiracetam more effective than phenytoin in seizure cessation in children with convulsive
status epilepticus that don’t respond to first-line treatment?

Sydney A. Santiago, PA-S
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirements For
The Degree of Master of Science
In
Health Sciences – Physician Assistant
Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

December 18, 2020

ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not “Is
levetiracetam more effective than phenytoin in seizure cessation in children with convulsive
status epilepticus that don’t respond to first-line treatment?”
Study design: Systematic review of three randomized controlled trials (RCTs) published in peerreviewed journals in English in 2019.
Data Sources: Three RCTs published in peer reviewed journals were found using Alt
HealthWatch, AMED, CINAHL Plus, and Scopus.
Outcome(s) Measured: Clinical cessation of seizure, defined as cessation of continuous
rhythmic clonic activity, was measured by the investigator after infusion of treatment.
Results: The study by Dalziel et al. showed a higher rate of seizure cessation in the phenytoin
group compared to the levetiracetam group as well as a clinically significant NNT of -10.
However, with a p-value of 0.18 and a 95% CI of -23.6 to 4.2 the results were not statistically
significant. In the study by Noureen et al. the rates of seizure cessation in the levetiracetam group
were significantly higher than those in the phenytoin group (P-value = 0.01). In the study by
Lyttle et al. there was a higher rate of seizure cessation in the levetiracetam group compared to
the phenytoin group along with an NNT of 10, however the results were not statistically
significant with a p value of 0.20.
Conclusions: The only study in this selective EBM review to yield statistically significant
results showed that levetiracetam is more effective than phenytoin in seizure cessation in
children with convulsive status epilepticus that don’t respond to first-line treatment. Due to the
variability of the results and limitations of each study, further research is needed to provide a
more concrete answer to the question at hand. Additionally, studies analyzing the safety and
efficacy of using both phenytoin and levetiracetam together as second line treatment may
provide critical information regarding the treatment of CSE in the future.
Key Words: levetiracetam, children, convulsive status epilepticus, randomized controlled trial
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INTRODUCTION
Convulsive status epilepticus (CSE) is a neurological emergency that is defined as an
unremitting seizure lasting longer than 5 minutes or multiple clinical seizures without interictal
return to baseline. CSE can affect anyone, however it is most commonly seen in patients with a
history of a seizure disorder who have had a recent change in their mediation regimen or are
noncompliant with their medications. Other causes in children include head trauma, infection,
fever, hypoxia, and cerebral malformations. If not treated in a timely manner, CSE can lead to
various neurologic sequelae, permanent neurodisability, or even death.
In the pediatric population, CSE is the most common neurological emergency
worldwide.1 The annual incidence is 20 per 100,000 children and accounts for 1-2% of all
emergency department visits.2 The estimated cost of CSE in a child is $9,000 per admission, but
the annual direct costs of CSE in the USA are estimated around $4 billion dollars.3 With 34% of
children developing neurologic sequelae and 3-5% resulting in mortality, providers need to be
quick to recognize and promptly treat CSE. 4 Physician assistants (PAs) have had an increasing
presence in emergency departments across the US and the need for them continues to rise. With
this change comes an opportunity for PAs to have a more involved role in critical care scenarios
such as CSE.
While the exact cause of CSE is unknown, recent research suggests that GABAA
inhibition becomes less effective and glutamates excitatory actions are enhanced.5 The longer
CSE lasts, the harder it is to terminate the seizure, leading to a greater risk of morbidity,
including neurologic complications such as neurodisability, learning disabilities, and drug
resistant epilepsy. The first line pharmacologic treatment in CSE is a benzodiazepine, most
commonly lorazepam or midazolam. If the seizure persists after 2 doses, second line therapy
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most commonly is with phenytoin, but other options include levetiracetam, valproate, and
phenobarbital. When these measures fail, patients require rapid sequence induction (RSI) and
intubation. Research regarding second line treatment options is widely inconsistent. Although
phenytoin is effective in around 60% of patients, it has an extensive side effect profile and can
cause fatal cardiac arrythmias. Levetiracetam is a broad-spectrum anticonvulsant that has
become increasingly popular because it has fewer adverse events and minimal drug interactions.
Although phenytoin and levetiracetam are both indicated as second line therapies, this paper
evaluates whether levetiracetam is more effective than phenytoin in cessation of CSE in children
that don’t respond to first line therapy.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is
levetiracetam more effective than phenytoin in seizure cessation in children with convulsive
status epilepticus that don’t respond to first-line treatment?”
METHODS
All articles were found using Alt HealthWatch, AMED, CINHL Plus, and Scopus. The
keywords used were levetiracetam, children, convulsive status epilepticus, and randomized
controlled trial. The studies were all published in peer-reviewed journals that were published in
English in 2019. Articles were chosen based on the relevance to my clinical question and
whether or not results were measured in POEMs. The inclusion criteria for this review were
RCTs that were peer reviewed, studies published in English after 2010, and subjects ages birth to
18 years. Exclusion criteria were studies published before 2010, subjects over the age of 18, and
studies not published in English.
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Three randomized controlled studies were selected for this review. Studies included
patients under 18 that presented to the emergency department with CSE that did not respond to
first line treatment with benzodiazepines. The interventions included levetiracetam 40 mg/kg IV
and phenytoin 20 mg/kg IV. The efficacy of each drug was measured by whether or not seizure
cessation occurred, which was determined by the investigator of each clinical trial.
The demographics and characteristics of the studies included in this review are outlined
below in table 1. The statistical significance of the outcomes measured were determined by ABI,
RBI, NNT, p value, and CI.
OUTCOMES MEASURED
All studied included in this review measured the effectiveness of interventions based off
of seizure cessation. This was determined by the investigators of each study who visually
evaluated the patients and determined whether there was clinical cessation of seizure activity. In
Dalziel et al., the senior most treating physician examined participants for increased tone, jerking
movements including nystagmoid eye movements, and level of consciousness based off of the
Alert, Voice, Pain, Unresponsive scale five minutes after the end of the drug infusion.4
Continued seizure activity was defined as increased tone or increased jerking movements. The
primary outcome in this study was video recorded when possible to be further reviewed by two
emergency physicians and one neurologist to assess for observer bias.4 In Noureen et al., the
outcome was measured 30 minutes after the end of the drug infusion by the senior treating
physician who assessed seizure activity based on increased tone, jerking movements, and the
level of consciousness.6 In Lyttle et al., the treating clinician continuously assessed for seizure
cessation, as defined by cessation of all rhythmic clonic activity, and measured the time from
randomization to cessation of seizure.1
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Table 1. Demographics and Characteristics of Included Studies
Study Type
Dalzi
el,
2019
(1)

RCT

#
Pts
234

Age

Nour
een,
2019
(2)

RCT

624

1yr14yr

Male and
Females 1–14
years with
generalized
CSE who
did not
responding to
two doses of
diazepam

Lyttle RCT
2019
(3)

404

6
mo18yr

Children of
either sex,
aged 6 months
to under 18
years,
presenting with
CSE that
required
second-line
treatment

3mo
-16
yrs

Inclusion
Criteria
Children aged
3 mo- 16 yrs
with CSE that
failed first line
therapy with 2
doses of a
benzodiazepine

Exclusion Criteria

W/
D
37

Children
previously
enrolled in the
study, regular use
of phenytoin or
levetiracetam,
administration of
second-line
anticonvulsants in
the past 24 h, CI or
allergy to
phenytoin or
levetiracetam
CSE due to major
head injury
Received
24
treatment other
than
benzodiazepine, on
assisted
ventilation, CSE
secondary to
hypertensive
encephalopathy,
head injury,
kidney or liver ds,
or electrolyte
derangement,
hypotension
symptoms
Those who did not 118
require second line
treatment
Those who did not
consent

Interventions
Phenytoin
20mg/kg IV or
IO infused over
20 minutes
diluted 1:4 with
0·9% sodium
chloride vs.
levetiracetam
40mg/kg IV or
IO infused over
5 minutes diluted
1:1 with 0·9%
sodium
chloride
Levetiracetam
IV 40 mg/kg
infused over 15
minutes vs.
phenytoin 20
mg/kg over 30
minutes

Levetiracetam
IV 40 mg/kg
infused over 5
minutes vs.
phenytoin 20
mg/kg over 20
minutes

4

Santiago, Levetiracetam and CSE

5

RESULTS
In the ConSEPT study by Dalziel et al., 234 children between ages three months and 16
years who presented to 13 qualifying emergency departments in Australia and New Zealand with
CSE that failed first line therapy with 2 doses of benzodiazepines were assessed.4 These
individuals were selected based on the inclusion and exclusion criteria noted above in table 1.
Participants were randomly assigned using a computer-generated sequence to either receive
20mg/kg of phenytoin or 40mg/kg of levetiracetam intravenously or intraosseous.4 After
randomization, 114 participants were assigned to receive phenytoin and 119 participants were
assigned to receive levetiracetam. Of the 115 participants randomly assigned to receive
phenytoin, one participant refused consent, three were intubated before phenytoin was
administered, and 15 had cessation of seizure activity before administration of the drug.4 Of the
119 participants randomly assigned to receive levetiracetam, two had to be intubated prior to
receiving the drug and 16 had seizure cessation before starting levetiracetam.4 The remaining 96
participants who received phenytoin and remaining 101 participants that received levetiracetam
were included in the modified intention-to-treat population analyzed in this review.
Participants were evaluated by the most senior treating physician five minutes after the
drug infusion was completed. In the levetiracetam group, 46 participants or 46% achieved
clinical cessation of seizure (Table 2).4 In the phenytoin group, 53 participants or 55% achieved
clinical cessation of seizure (Table 2).4 When comparing the two treatment groups, there was not
a statistically significant difference (p= 0.18).4 Additionally, the 95% confidence interval of 23.6 to 4.2 is wide and crosses 0, suggesting the treatment effect is not precise (Table 2).4 The
NNT was -10, which is a large negative treatment effect suggesting that if 10 people are treated
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with levetiracetam, one fewer participant would have seizure cessation than if they received
phenytoin. The RBI was -0.18 and the ABI was -0.10 (Table 3).
Noureen et al. assessed 624 children ages one to 14 years old who presented to the
emergency department of The Children’s Hospital and The Institute of Child Health in Multan,
Pakistan between January 2014 to June 2018 with CSE that did not respond to two doses of
diazepam.6 Refer to Table 1 for specific inclusion and exclusion criteria. All participants were
randomly assigned using a sealed envelope system to either receive levetiracetam 40 mg/kg IV
infused over 15 minutes or 20 mg/kg phenytoin IV infused over 30 minutes.6 After
randomization 300 participants were allocated to the levetiracetam group and 324 participants
were allocated to the phenytoin group. However, 24 participants randomized to the phenytoin
group either did not consent or withdrew from the study, leaving 300 participants to receive
phenytoin.6 Participants were evaluated from the start of the infusion until 30 minutes after
completing the infusion. In the levetiracetam group 278 participants or 92.7% achieved seizure
cessation (Table 2).6 In the phenytoin group 250 participants or 83.3% achieved seizure cessation
(Table 2).6 The p-value was 0.01, indicating a statistically significant difference between the
treatment groups (Table 2).7 No confidence interval was provided. The NNT was 17, suggesting
a large positive treatment effect. The RBI was 0.09 and the ABI was 0.06 (Table 3).
In the EcLiPSE study by Lyttle et al., 404 children aged six months to 18 years that
presented at 30 different UK emergency departments between July 2015 and April 2018 with
CSE requiring second line treatment were assessed.1 Specific inclusion and exclusion criteria can
be found in Table 1. A statistician with no further involvement in the study produced a
computer-generated randomization schedule and delivered them to eligible sites in tamper-proof
envelopes for treating clinicians to open after confirmation of eligibility.1 Of the 404
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participants, 212 were assigned levetiracetam and 192 were assigned phenytoin. In the
levetiracetam group, 51 participants did not require second line treatment and nine participants
did not consent, leaving 152 participants for analysis.1 In the phenytoin group, 42 participants
did not require second line therapy and 16 declined consent, leaving 134 participants for
analysis.1
The primary outcome measured in the EcLiPSE study was the time from randomization
to cessation of seizure. In order to maintain consistency with the other studies, whether or not
each trial drug provided seizure cessation was analyzed to determine drug efficacy rather than
analyzing the length of time to seizure cessation. Seizure activity was terminated in 106
participants or 70% in the levetiracetam group and 86 participants or 64% in the phenytoin group
(Table 2).1 There was not a statistically significant difference between the two treatment groups
(p=0.20).1 No confidence interval was provided for this outcome. Despite an insignificant pvalue, the NNT was 10, suggesting a large positive treatment effect (Table 3). The RBI was
calculated as 0.11 and the ABI as 0.10 (Table 3).
Table 2. Seizure Cessation, p-value, and 95% CI by Study
Study
Levetiracetam Phenytoin
p-value
Dalziel et al.
46 (46%)
53 (55%)
0.18
Noureen et al. 278 (92.7%)
250 (83.3%) 0.01
Lyttle et al.
106 (70%)
86 (64%)
0.20

95% CI
-23.6 to 4.2
---

Table 3. Calculations for Treatment by Study
Study
RBI
ABI
NNT
Dalziel et al.
-0.18
-0.10
-10
Noureen et al. 0.09
0.06
17
Lyttle et al.
0.11
0.10
10
DISCUSSION
Convulsive status epilepticus is one of the most commonly encountered neurological
emergencies in emergency departments around the world. The treatment is complex and
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constantly evolving. Beyond first line treatment with benzodiazepines, there is a lack of strong
evidence to guide additional pharmacologic treatment prior to RSI and intubation. While the aim
of this selective review was to determine if levetiracetam is more effective than phenytoin in
seizure cessation in children with convulsive status epilepticus that don’t respond to first-line
treatment, the articles in this review did not provide a clear answer.
All three studies evaluated seizure cessation. Dalziel et al. demonstrated higher rates of
seizure cessation in the phenytoin group than in the levetiracetam group, but the results were not
statistically significant.4 An additional feature of the Dalziel et al. study was that some
participants who did not respond to second line treatment were given the alternate study drug
immediately following failure of the first.4 They found that this additional treatment reduced the
need for RSI and intubation by about 50%, but formal studies are needed for further
investigation.4 Lyttle et al. and Noureen et al. demonstrated higher rates of seizure cessation in
the levetiracetam group than the phenytoin group, however only Noureen et al. showed a
statistically significant difference between the two treatment groups.1,6 While the Lyttle et al.
study did not show a statistically significant difference between treatments, the NNT was 10,
suggesting a large treatment effect and clinical significance.1 Of consideration, the seizure
cessation rates of both levetiracetam and phenytoin were significantly higher in the Noureen et
al. study than the other studies analyzed in this selective review, potentially due to specific
characteristics of study participants.6 Further studies are needed to solidify the findings.
There were various limitations to all studies analyzed in this selective review. First, the
outcomes were all subjective based on the treating clinician and their clinical judgment.
Although this could have played a role in the study outcomes, it mirrors real-life clinical practice
in the sense that EEGs are not typically available in the setting of CSE and outcomes are
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continuously assessed by the treating physician.4 Additionally, the physicians were not masked
to treatment allowing for possible bias. However, given the life-threatening nature of CSE, there
is a low probability that this occurred. Next, there was a longer time to assessment of seizure
cessation in the phenytoin group due to the slower infusion rate.1,4,6 This could have allowed
more time for the first line therapies to take effect or a natural decline of seizure activity.
Another factor to consider when interpreting the findings is the extensive use of levetiracetam as
a maintenance therapy.5 Phenytoin is not widely used as maintenance therapy due to its adverse
effects. For example, in Lyttle et al., 55 participants were taking levetiracetam as a maintenance
therapy compared to 1 participant taking phenytoin as maintenance therapy.1
There are additional limitations to consider when analyzing the studies by Dalziel et al.
and Lyttle et al. When videos of the primary outcomes in Dalziel et al. were further reviewed by
two emergency physicians and one neurologist to assess for observer bias, the group
unanimously disputed the outcomes of four participants in the phenytoin group and three
participants in the levetiracetam group.4 Although the independent reviewers found evidence
conflicting with the initial assessment, it occurred in similar numbers in each of the treatment
groups.4 Finally, a limitation of the Lyttle et al. study was that three participants in the
levetiracetam group received phenytoin but were still analyzed in the levetiracetam group.1
However, due to the fact that the three participants only made up 2% of the levetiracetam group,
it is unlikely this error significantly altered the results.
CONCLUSION
Although the use of levetiracetam as a second line treatment for children with CSE
seemed promising, the three studies in this selective EBM review did not agree on whether or not
it is more effective than phenytoin in cessation of seizures. Similar to this review, previous
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studies regarding the use of phenytoin and levetiracetam as second line treatment in patients with
CSE have provided contradicting or inconclusive results. The variability in the results of the
three studies selected for this EBM review suggest future studies are necessary to provide a more
concrete answer. Currently there is more research being conducted on adults with CSE rather
than children with CSE, making continued research on second line treatments in pediatric CSE
even more important.1
While the results of this systematic review do not show that one drug is more efficacious
than the other in seizure cessation, it does suggest that both levetiracetam and phenytoin are
effective in cessation of CSE in children who do not respond to first line treatment. An analysis
regarding safety and tolerability of phenytoin and levetiracetam may help provide more insight
into which drug would be a better second line option. As previously stated, the Dalziel et al.
study found that the use of phenytoin and levetiracetam back-to-back as second line treatment
improved seizure cessation rates and decreased the need for RSI by 50%.4 Additional studies
analyzing the safety and efficacy of using both phenytoin and levetiracetam together as second
line treatment are needed and may provide critical information regarding the treatment of CSE in
the future.
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